Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. April 2018 09:00 ET | Quelle: Biodesix, Inc.

New Data Shows Biodesix Blood Test Reliably Detects Additional Mutations in Patients with NSCLC

BOULDER, Colo., April 18, 2018 (GLOBE NEWSWIRE) -- Biodesix®, Inc. is presenting new data today demonstrating the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably...
17. April 2018 09:00 ET | Quelle: Cyclacel

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
16. April 2018 07:00 ET | Quelle: Cyclacel

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
05. April 2018 10:00 ET | Quelle: Biodesix, Inc.

Biodesix Announces Data To Be Presented at AACR Annual Meeting 2018

BOULDER, Colo., April 05, 2018 (GLOBE NEWSWIRE) -- Biodesix®, Inc. will present new data confirming the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably detect key...
15. März 2018 07:00 ET | Quelle: Cyclacel

Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

BERKELEY HEIGHTS, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...